Entecavir Accord

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

Энтекавир

Available from:

Accord Healthcare S.L.U.

ATC code:

J05AF10

INN (International Name):

entecavir

Therapeutic group:

Antivirusni lijekovi za sustavnu uporabu

Therapeutic area:

Hepatitis B, kronični

Therapeutic indications:

Entecavir Accord is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with: , compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis. , dekompenziranom bolesti jetre . Kao компенсированные i dekompenziranom bolesti jetre, ovaj pokazatelj temelji se na podacima iz kliničkih istraživanja u naivnih pacijenata nukleozida s pozitivnim rezultatom testa na hbeag i hbeag-negativni HBV-infekcije. Što se tiče bolesnika s refluksom hepatitis B lamivudina. Энтекавир Accord je također indiciran za liječenje kronične HBV-infekcije u nukleozida naivan pedijatrijska bolesnika od 2 do.

Product summary:

Revision: 5

Authorization status:

odobren

Authorization date:

2017-09-25

Patient Information leaflet

                                37
B. UPUTA O LIJEKU
38
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
_ _
ENTEKAVIR ACCORD 0,5 MG FILMOM OBLOŽENE TABLETE
ENTEKAVIR ACCORD 1 MG FILMOM OBLOŽENE TABLETE
entekavir
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE UZIMATI OVAJ
LIJEK JER SADRŽI VAMA VAŽNE
PODATKE.
-
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
-
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
-
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako su
njihovi znakovi bolesti jednaki Vašima.
-
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To uključuje
i svaku moguću nuspojavu koja nije navedena u ovoj uputi. Pogledajte
dio 4.
_ _
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je Entekavir Accord
i za što se koristi
2.
Što morate znati prije nego počnete uzimati Entekavir Accord
3.
Kako uzimati Entekavir Accord
4.
Moguće nuspojave
5.
Kako čuvati Entekavir Accord
6.
Sadržaj pakiranja i druge informacije
1.
ŠTO JE ENTEKAVIR ACCORD
I ZA ŠTO SE KORISTI
ENTEKAVIR ACCORD TABLETE SU ANTIVIRUSNI LIJEK, KOJI SE PRIMJENJUJE ZA
LIJEČENJE KRONIČNE
(DUGOTRAJNE) INFEKCIJE VIRUSOM HEPATITISA B (HBV) U ODRASLIH.
Entekavir Accord se može
primjenjivati u osoba koje imaju oštećenu jetru, ali ona još
ispravno radi (kompenzirana bolest jetre) i
u osoba koje imaju oštećenu jetru i ona ne radi ispravno
(dekompenzirana bolest jetre).
ENTEKAVIR ACCORD
TABLETE
PRIMJENJUJU SE I ZA LIJEČENJE KRONIČNE (DUGOTRAJNE) HBV INFEKCIJE U
DJECE I ADOLESCENATA U DOBI OD 2 GODINE DO MANJE OD 18 GODINA
. Entekavir Accord se može
primijeniti u djece čija je jetra oštećena, ali još uvijek
ispravno radi (kompenzirana bolest jetre)
Infekcija virusom hepatitisa B može dovesti do oštećenja jetre.
Entekavir Accord
smanjuje količinu
virusa u Vašem tijelu i poboljšava stanje jetre.
2.
ŠTO MORATE ZNATI PRIJE NEGO POČNETE UZIMATI ENTEKAVIR ACCORD
NEMOJTE UZIMATI ENTEKAVIR ACCORD
-
AKO
STE ALERGIČNI (PREOSJETLJIVI)
na entekavir ili neki dru
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
Entekavir Accord 0,5 mg filmom obložene tablete
Entekavir Accord 1 mg filmom obložene tablete
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Entekavir Accord 0,5 mg filmom obložene tablete
Jedna tableta sadrži entekavir hidrat ekvivalentan 0,5 mg entekavira.
Entekavir Accord 1 mg filmom obložene tablete
Jedna tableta sadrži entekavir hidrat ekvivalentan 1 mg entekavira.
Pomoćne tvari s poznatim učinkom
Jedna filmom obložena tableta od 0,5 mg sadrži 26 mg polisaharida
soje.
Jedna filmom obložena tableta od 1 mg sadrži 52 mg polisaharida
soje.
Za cjeloviti popis pomoćnih tvari vidjeti dio 6.1.
3.
FARMACEUTSKI OBLIK
Filmom obložena tableta (tableta)
Entekavir Accord 0,5 mg filmom obložene tablete
Bijele do bjelkaste bikonveksne filmom obložene tablete trokutastog
oblika s utisnutom oznakom „J“
na jednoj strani i „110“ na drugoj strani.
Dimenzije: dužina 8,70 mm ± 0,20 mm, širina 8,40 mm ± 0,20 mm i
debljina 3,40 mm ± 0,30 mm.
Entekavir Accord 1 mg filmom obložene tablete
Ružičaste bikonveksne filmom obložene tablete trokutastog oblika s
utisnutom oznakom „J“ na jednoj
strani i „111“ na drugoj strani.
Dimenzije: dužina 11,00 mm ± 0,20 mm, širina 10,60 mm ± 0,20 mm i
debljina 4,20 mm ± 0,30 mm.
4.
KLINIČKI PODACI
4.1
TERAPIJSKE INDIKACIJE
Entekavir Accord je indiciran za liječenje kronične infekcije
virusom hepatitisa B (HBV) (vidjeti dio
5.1) u odraslih s:
•
kompenziranom bolešću jetre i dokazanom aktivnom replikacijom
virusa, konstantno povišenim
razinama alanin aminotransferaze (ALT) u serumu i histološki
dokazanom aktivnom upalom
i/ili fibrozom.
•
dekompenziranom bolešću jetre (vidjeti dio 4.4)
Ova se indikacija temelji, kako za kompenziranu, tako i za
dekompenziranu bolest jetre, na podacima
iz kliničkog ispitivanja u bolesnika s HBeAg pozitivnom i HBeAg
negativnom HBV infekcijom koji
3
prethodno nisu bili liječeni analozima nukleozida. Za bolesnike s
hepatitisom B refrakternim na
liječenje lamivudi
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 29-07-2022
Public Assessment Report Public Assessment Report Bulgarian 26-01-2018
Patient Information leaflet Patient Information leaflet Spanish 29-07-2022
Public Assessment Report Public Assessment Report Spanish 26-01-2018
Patient Information leaflet Patient Information leaflet Czech 29-07-2022
Public Assessment Report Public Assessment Report Czech 26-01-2018
Patient Information leaflet Patient Information leaflet Danish 29-07-2022
Public Assessment Report Public Assessment Report Danish 26-01-2018
Patient Information leaflet Patient Information leaflet German 29-07-2022
Public Assessment Report Public Assessment Report German 26-01-2018
Patient Information leaflet Patient Information leaflet Estonian 29-07-2022
Public Assessment Report Public Assessment Report Estonian 26-01-2018
Patient Information leaflet Patient Information leaflet Greek 29-07-2022
Public Assessment Report Public Assessment Report Greek 26-01-2018
Patient Information leaflet Patient Information leaflet English 29-07-2022
Public Assessment Report Public Assessment Report English 26-01-2018
Patient Information leaflet Patient Information leaflet French 29-07-2022
Public Assessment Report Public Assessment Report French 26-01-2018
Patient Information leaflet Patient Information leaflet Italian 29-07-2022
Public Assessment Report Public Assessment Report Italian 26-01-2018
Patient Information leaflet Patient Information leaflet Latvian 29-07-2022
Public Assessment Report Public Assessment Report Latvian 26-01-2018
Patient Information leaflet Patient Information leaflet Lithuanian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 29-07-2022
Public Assessment Report Public Assessment Report Lithuanian 26-01-2018
Patient Information leaflet Patient Information leaflet Hungarian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 29-07-2022
Public Assessment Report Public Assessment Report Hungarian 26-01-2018
Patient Information leaflet Patient Information leaflet Maltese 29-07-2022
Public Assessment Report Public Assessment Report Maltese 26-01-2018
Patient Information leaflet Patient Information leaflet Dutch 29-07-2022
Public Assessment Report Public Assessment Report Dutch 26-01-2018
Patient Information leaflet Patient Information leaflet Polish 29-07-2022
Public Assessment Report Public Assessment Report Polish 26-01-2018
Patient Information leaflet Patient Information leaflet Portuguese 29-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 29-07-2022
Public Assessment Report Public Assessment Report Portuguese 26-01-2018
Patient Information leaflet Patient Information leaflet Romanian 29-07-2022
Public Assessment Report Public Assessment Report Romanian 26-01-2018
Patient Information leaflet Patient Information leaflet Slovak 29-07-2022
Public Assessment Report Public Assessment Report Slovak 26-01-2018
Patient Information leaflet Patient Information leaflet Slovenian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 29-07-2022
Public Assessment Report Public Assessment Report Slovenian 26-01-2018
Patient Information leaflet Patient Information leaflet Finnish 29-07-2022
Public Assessment Report Public Assessment Report Finnish 26-01-2018
Patient Information leaflet Patient Information leaflet Swedish 29-07-2022
Public Assessment Report Public Assessment Report Swedish 26-01-2018
Patient Information leaflet Patient Information leaflet Norwegian 29-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 29-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 29-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 29-07-2022

Search alerts related to this product